Alterity Therapeutics annual free cash flow
2016
2017
2018
2019
2020
2021
2022
2023
2024
Alterity Therapeutics Free Cash Flow (FCF) History (ATHE)
Alterity Therapeutics reported −$12.6M in free cash flow for fiscal 2024, an increase of $7.4M from the previous fiscal year, with a free cash flow margin of −294.13%.
View full Alterity Therapeutics company overviewAlterity Therapeutics free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2024 | 2024-06-30 | −$12.6M | $7.4M | — | −294.13% |
| 2023 | 2023-06-30 | −$20.0M | −$7.6M | — | −509.64% |
| 2022 | 2022-06-30 | −$12.4M | $4.9M | — | −242.42% |
| 2021 | 2021-06-30 | −$17.3M | −$7.9M | — | −384.84% |
| 2020 | 2020-06-30 | −$9.4M | $4.5M | — | −6755.91% |
| 2019 | 2019-06-30 | −$14.0M | −$7.7M | — | −275.94% |
| 2018 | 2018-06-30 | −$6.3M | −$414,595 | — | −3135.39% |
| 2017 | 2017-06-30 | −$5.9M | $1.5M | — | −4451.04% |
| 2016 | 2016-06-30 | −$7.4M | — | — | −5201.87% |
Alterity Therapeutics quarterly free cash flow
No reported data
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|
Alterity Therapeutics free cash flow growth trends
Over the last five reported fiscal years, free cash flow grew from −$14.0M to −$12.6M, a net increase of $1.4M.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Alterity Therapeutics filings at SEC.gov ↗